# RESULTS PRESENTATION 3Q22



- • •
- • •
- ••••

•

- • •
  - . . . .
  - ••••



November 10<sup>th</sup>, 2022



#### DISCLAIMER

Rio de Janeiro, November 10<sup>th</sup>, 2022 - **YDUQS Participações S.A.**, one of the largest private organizations in Brazil's higher education private sector, presents its **results for the third quarter of 2022 (3Q22).** 


The Company's financial information is presented based on consolidated numbers, in Brazilian Reais, in accordance with the Brazilian Corporation Law and the accounting practices adopted in Brazil (BRGAAP), already in accordance with the International Financial Reporting Standards (IFRS), including IFRS-16.

This document may have forward looking statements that are subject to risks and uncertainties that may lead such expectations to not materialize or substantially differ from expectations. These forecasts express the opinion only for the date they were made, and the Company does not undertake to update them in the light of new information.

> THE USE BY YDUQS Participações S.A. OF ANY MSCI ESG RESEARCH LLC OR ITS AFFILIATES ("MSCI") DATA, AND THE USE OF MSCI LOGOS, TRADEMARKS, SERVICE MARKS OR INDEX NAMES HEREIN, DO NOT CONSTITUTE A SPONSORSHIP, ENDORSEMENT, RECOMMENDATION, OR PROMOTION OF YDUQS Participações S.A. BY MSCI. MSCI SERVICES AND DATA ARE THE PROPERTY OF MSCI OR ITS INFORMATION PROVIDERS, AND ARE PROVIDED 'AS-IS' AND WITHOUT WARRANTY. MSCI NAMES AND LOGOS ARE TRADEMARKS OR SERVICE MARKS OF MSCI.

### 3Q22 HIGHLIGHTS


#### 3Q22 YDUQS



#### 3Q22 YDUQS


#### PREMIUM

Q



Net revenue adjusted by the effects of laws and court decisions in 2021. | EBITDA adjusted by non-recurring effects.
 Improved renewal of students who were delinquent, who benefited from laws and court decisions to renew.

### DIGITAL LEARNING



(1) Net revenue adjusted by the effects of laws and court decisions in 2021. | EBITDA adjusted by non-recurring effects.

(2) 2Q21 Intake: 2x greater vs 2Q22.

Q


(3)

1Q22 Intake: 60% greater vs 1Q21.

3Q22 YDUQS

EBITDA 4Q22


#### **ON-CAMPUS**





## 2021 ENADE RESULTS


YDUQS's progress by ENADE concept (%)



Satisfactory concepts: Score 3 | Scores 4 and 5

Dissatisfactory concepts: Scores 1 and 2

Players' ranking by concept in 2021 (%)



#### Distance Learning (DL)

HOPER

- The 2021 cycle has many course similarities to 2017 and 2019, with an increased share of teaching degrees, but without the Q participation of engineering and architecture programs – very different from 2018
- On-campus: We improved the satisfactory concepts by 11 p.p. vs 2017: All Brazilian regions where we have on-campus units Q recorded better satisfactory concepts in the ENADE. Rio stood out with +19 p.p..
  - DL: Only Ydugs and another player achieved scores 4 and 5 in this cycle




Webinar about **2021 ENADE Results** 

3Q22

YDUQS

REVENUE: PREMIUM AND DIGITAL REPRESENT 55% OF TOTAL




Q

3Q22

YDUQS


### COSTS AND EXPENSES: STRICT COST CONTROL






(1) Costs and expenses adjusted by non-recurring effects, excluding depreciation and amortization.

### HIGHEST ADJUSTED EBITDA IN OUR HISTORY



### ADJUSTED NET INCOME

3Q22 YDUQS





### CASH FLOW AND CAPEX


R\$ million	3Q21	3Q22	$\Delta \%$
Adjusted EBITDA ex-IFRS 16	307	323	5%
Working capital variation	49	71	46%
Taxes (IT/SC)	(12)	(1)	-91%
Operating Cash Flow	344	393	14%
Сарех	(151)	(123)	-18%
Free Cash Flow	193	270	40%
Operating Cash Conversion <sup>(1)</sup>	11 <b>2</b> %	1 <b>22</b> %	10 p.p.

#### R\$ 461 million

9M22 Free Cash Flow post capex (+34% YoY)

Q





- > 9M22 Capex ends at R\$333 million (+2% vs 9M21)
- 2022 Estimated Capex: R\$ 500 million vs R\$ 544 million in 2021 (reduction of -8%)

# SUSTAINABILITY (ESG)

Q

 $\mathbf{O}$ 



What we presented ir	n 1H22	P	Progress in 3Q22			
Environment			GHG emissions inventory: Scope 3 practically finalized			
Renewable sources: 81% of total energy consumption GHG Diagnosis Scopes 1 and 2 in June/2022 Scope 3 ongoing		d 2 in June/2022	<ul> <li>(83% concluded) – Completion forecast: Dec/22.</li> <li>2<sup>nd</sup> Trainee Program for blacks with registration record –</li> </ul>			
			5,959 registrations.			
Social						
Student Base 56% Black 75% family income <4 minimum wages	<b>84% of employees</b> at corporate offices are former YDUQS's students	<b>33% women</b> <b>31% black</b> at high level mgt	Black Teachers – 207 new professors hired, 56% above our goal.			
			<ul> <li>Literacy program: 14 classes open with 300 active students and 800 already literate, through an</li> </ul>			
Governance			exclusive methodology.			
<b>True Corporation</b> No controlling shareholder	<b>100% independent</b> Board members	<b>44% of high level m</b> <b>with ESG goals</b> tied to variable compense				
			institute Rede			

#### FINAL REMARKS



In a **challenging macroeconomic scenario**, we **continue to grow** with a **strong portfolio** and focus on **cost efficiency**. We expect to **keep growing** even if this scenario persists, and we are ready for **a strong acceleration** with an **economic recovery**.

- 9M22 Free cash flow post capex: R\$461 million (+34% vs 9M21)
- > Net Revenue and adjusted EBITDA grow +3% vs 3Q21
- Premium and Digital reach
   55% of Net Revenue and ~70% of total EBITDA

- Adjusted Costs and Expenses (ex-D&A and IFRS 16) -1.p.p. (%NOR) Adjusted EBITDA margin stable at 36% vs 3Q21
- **Capex drops** -18% vs 3Q21 Expected 2022 capex reduction of 8% vs 2021



#### What we presented in 1H22

Challenging intake, no growth expectation vs 2H21 but expected positive evolution on recurring freshmen tickets

Results expected to be similar to 2H21 results, with 3<sup>rd</sup> quarter with a slightly inferior performance and 4<sup>th</sup> quarter superior



Results and updated expectations



3Q22 Results superior to 3Q21 4Q22 EBITDA with growth of 2 digits YoY YDUQS in 2022

7.4-7.5 thousand Undergraduate medicine student base

**2,500** Total DL centers

**3.2-3.4 thousand** Students/campus

Capex: R\$500 million (Long Term at 7-8% Net Revenue)

14



IR Contact ri@yduqs.com.br www.yduqs.com.br

#### MEDICAL SEATS OFFERING BY UNIT (Undergraduate)

Q

			3Q22	Full Potential <sup>(1)</sup>	
Units	State	Authorized seats	<b>Student Base</b> (Thousand)	Authorized seats	<b>Student Base</b> (Thousand)
Presidente Vargas	RJ	240	1.6	240	1.7
Città	RJ	170	1.1	170	1.2
Juazeiro do Norte	CE	100	0.7	100	0.7
Ribeirão Preto	SP	76	0.5	76	0.5
Teresina   Facid	ΡI	110	0.8	110	0.8
Alagoinhas	BA	65	0.4	165	1.2
Jaraguá do Sul	SC	150	0.4	150	1.1
Juazeiro	BA	155	0.8	155	1.1
Angra dos Reis	RJ	89	0.5	155	1.1
Canindé	CE	50	0.2	150	1.1
Cáceres	MT	50	0.2	50	0.4
Castanhal	PA	50	0.1	150	1.1
Quixadá	CE	50	0.1	150	1.1
Açailândia	MA	50	0.1	150	1.1
Iguatu	CE	50	0.05	150	1.1
Ji-Paraná   Famejipa	RO	50	0.05	150	1.1
Unijipa	RO	28	0.03	28	0.2
Total		1,533	7.5	2,299	16.5

(1) Considers the expansion to the maximum capacity of granted seats (+100 seats/year) in all Mais Médicos units. Student base includes ProUni and FIES.